Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SCAVENGING ON SEPSIS. DEVELOPMENT OF SEPSIS SPECIFIC DRUGS FROM HUMAN SCAVENGER RECEPTORS

Project description

A bacterial scavenger as a new sepsis treatment

Upon severe infection by bacterial or fungal pathogens, our body may elicit an imbalanced response known as sepsis. Sepsis may lead to multi-organ dysfunction, septic shock and death. The EU-funded SEPSCAV project proposes an alternative or adjunctive treatment to current antibiotic administration in sepsis. The generated biological drug is based on the human scavenger lymphocyte receptor CD6 encountered on some blood cells known for its capacity to interact with and neutralise core structural components of microbes. Administration of the drug in a preclinical animal model showed it to have protective properties and wide-spectrum bactericidal and anti-inflammatory action. SEPSCAV will introduce injectable CD6 derivatives to the market of sepsis therapeutics.

Objective

Sepsis is a major a life-threatening condition caused by bacterial or fungal infections leading to cardiovascular collapse (septic shock), multi-organ dysfunction syndrome (MODS) and death, and claims more lives that bowel and breast cancer combined. The human Scavenger-receptors are naturally occurring proteins on some blood cells that interact and neutralize core structural components of microbes, providing a novel therapeutic strategy for wide-spectrum sepsis treatment and an alternative to current antibiotic and adjunctive therapeutic approaches of limited success. Sepsia Therapeutics is a R&D start up company developing SIXTIDE, a peptide-drug based on human scavenger lymphocyte receptor CD6, with dual bactericidal and anti-inflammatory action, which protects mice from death in experimental sepsis, in a time- and dose-dependent manner. SIXTIDE mode of action inhibits bacterial growth and blocks the pro-inflammatory properties of bacterial toxins. Sepsia Therapeutics holds IPR on the use of CD6 and CD6 derivatives in the treatment of infection and inflammation disorders and aims for market entry through injectable SIXTIDE.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

SEPSIA THERAPEUTICS SL
Net EU contribution
€ 50 000,00
Address
PLAZA EUROPA NUM 9 11 PLANTA 13 TORRE INBISA
08908 L HOSPITALET DE LLOBREGAT
Spain
SME
Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00